Gutterman J U, Mavligit G M, Reed R, Burgess M A, Gottlieb J, Hersh E M
Cancer Treat Rep. 1976 Feb;60(2):177-82.
Combination studies of immunotherapy and DTIC chemotherapy for patients with malignant melanoma are described. At our institute the combination of bacillus Calmette-Guérin (BCG) with DTIC, or DTIC plus methyl-CCNU, has resulted in augmentation of remissions in areas regional to BCG immunization, prolongation of chemotherapy-induced remissions, and significant prolongation of survival compared to the use of DTIC chemotherapy without immunotherapy. Data from other centers have shown that augmentation of remissions for melanoma patients occurred when BCG was combined with DTIC, vincristine, and allogeneic tumor cells. Finally, another study has shown that DTIC combined with BCG has prolonged the disease-free interval and survival in melanoma patients with regional lymph node metastases. The potential inhibition of DTIC metabolism by BCG or Corynebacterium parvum is discussed.
本文描述了针对恶性黑色素瘤患者的免疫疗法与达卡巴嗪（DTIC）化疗的联合研究。在我们研究所，卡介苗（BCG）与DTIC联合，或DTIC加甲基环己亚硝脲，与单纯使用DTIC化疗相比，已导致卡介苗免疫区域的缓解增加、化疗诱导缓解期延长以及生存期显著延长。其他中心的数据表明，当卡介苗与DTIC、长春新碱和同种异体肿瘤细胞联合使用时，黑色素瘤患者的缓解增加。最后，另一项研究表明，DTIC与卡介苗联合可延长区域淋巴结转移的黑色素瘤患者的无病间期和生存期。文中还讨论了卡介苗或短小棒状杆菌对DTIC代谢的潜在抑制作用。
